Dovitinib Dilactic acid (CAS 852433-84-2)

Dovitinib Dilactic acid, also known scientifically as TKI258 Dilactic acid, is a potent and selective inhibitor of receptor tyrosine kinases (RTKs), which play a role in the signaling pathways that regulate cell proliferation and survival. Its mechanism of action is centered on the inhibition of multiple RTK families, including the fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) families. This broad spectrum of activity allows Dovitinib Dilactic acid to interfere with the angiogenic processes and tumor growth by blocking the signaling pathways that are essential for the development and maintenance of blood vessels in tumors, as well as the pathways involved in the proliferation and survival of cancer cells. In research applications, Dovitinib Dilactic acid serves as useful for studying the role of RTKs in various cellular processes and disease states, particularly in the field of oncology, where understanding the molecular basis of tumor growth and progression is critical for the development of new therapeutic strategies.